Evidence map›Paper›PMID 39350555›Full record

ArticleInfectious disorders drug targets2025

Structural Prediction and Antigenic Analysis of ROP18, MIC4, and SAG1 Proteins to Improve Vaccine Design against

Tooran Nayeri, Shahabeddin Sarvi, Mahdi Fasihi-Ramandi, Hossein Asgarian-Omran, Abolghasem Ajami, Zahra Hosseininejad, Samira Dodangeh, Ahmad Daryani

Abstract read
PubMed Publisher
In one paragraph

Article in Infectious disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. HarnessingAnnals of medicine · 2026
    Review
  2. Veterinary sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tooran NayeriInfectious and Tropical Diseases Research Center, Dezful University of Medical Sciences, Dezful, Iran.ORCID 0000-0001-5766-0120
Shahabeddin SarviDepartment of Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Mahdi Fasihi-RamandiMolecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Hossein Asgarian-OmranImmunology Department, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Abolghasem AjamiImmunology Department, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Zahra HosseininejadDepartment of Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Samira DodangehDepartment of Medical Parasitology and Mycology, Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
Ahmad DaryaniDepartment of Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundToxoplasmosis is a cosmopolitan infectious disease in warmblooded mammals that poses a serious worldwide threat due to the lack of effective medications and vaccines.

aimsThe purpose of this study was to design a multi-epitope vaccine using several bioinformatics approaches against the antigens of

methodsThree proteins of

resultsRMS protein had 545 amino acids with a molecular weight (MW) of 58,833.46 Da and a theoretical isoelectric point (IP) of 6.47. The secondary structure of RMS protein contained 21.28% alpha-helix, 24.59% extended strand, and 54.13% random coil. In addition, evaluation of antigenicity and allergenicity showed the protein to be an immunogen and nonallergen. The results of the Ramachandran plot indicated that 76.4%, 12.9%, and 10.7% of amino acid residues were incorporated in the favored, allowed, and outlier regions respectively. ΔG of the best-predicted mRNA secondary structure was -593.80 kcal/mol which indicates a stable loop is not formed at the 5' end.

conclusionFinally, the accuracy and precision of the

Indexed as

Antigens, ProtozoanMembrane ProteinsProtozoan ProteinsProtozoan VaccinesToxoplasmaToxoplasmosisComputational BiologyComputer SimulationEpitopes, B-LymphocyteEpitopes, T-LymphocyteHumansProtein Serine-Threonine KinasesAntigens, ProtozoanEpitopes, B-LymphocyteEpitopes, T-LymphocyteMembrane ProteinsProtein Serine-Threonine KinasesProtozoan ProteinsProtozoan VaccinesROP18 protein, Toxoplasma gondiiSAG1 antigen, Toxoplasmain silicoMIC4ROP18SAG1Toxoplasma gondiivaccine.

Identifiers

PMID39350555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.